Multilaboratory Evaluation of a Viability Assay for Measurement of Opsonophagocytic Antibodies Specific to the Capsular Polysaccharides of Streptococcus pneumoniae
- 1 November 2003
- journal article
- research article
- Published by American Society for Microbiology in Clinical and Vaccine Immunology
- Vol. 10 (6) , 1019-24
- https://doi.org/10.1128/cdli.10.6.1019-1024.2003
Abstract
Opsonophagocytosis is a correlate of protection that measures the functional activity of vaccine-induced antibodies. A standardized opsonophagocytosis assay (OPA) should be used as part of the evaluation of current and future pneumococcal (Pnc) polysaccharide (Ps)-based vaccines. We enrolled five laboratories to evaluate a previously standardized viability OPA. Each laboratory was provided with a detailed OPA protocol, seven target Pnc strains (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F), two quality control sera and 12 paired sera (blinded) from adult donors who received one dose of the 23-valent Pnc Ps vaccine. Laboratories sent their results to the Centers for Disease Control and Prevention for analysis. Sera were tested in duplicate (single run), and the results were averaged to yield a single OPA titer (≥50% killing) for each serum sample. The percentage of sera within one or two dilutions of the calculated median OPA titer was determined for each laboratory and for each serotype. In general, laboratories were capable of detecting OPA titers within one or two dilutions of the median for at least 75 and 88%, respectively, of the sera tested. The level of agreement with the median OPA titers varied depending on the participating laboratory (overall agreement = 0.8 [99% confidence interval = 0.75 to 0.85]). All OPA median titers reported for quality control sera were within one dilution of the expected titer. We conclude that this OPA can be done in multiple laboratories with a high degree of interlaboratory reproducibility.Keywords
This publication has 22 references indexed in Scilit:
- Chromogenic Assay Measuring Opsonophagocytic Killing Capacities of Antipneumococcal AntiseraClinical and Diagnostic Laboratory Immunology, 2001
- Comparison of a Classical Phagocytosis Assay and a Flow Cytometry Assay for Assessment of the Phagocytic Capacity of Sera from Adults Vaccinated with a Pneumococcal Conjugate VaccineClinical and Diagnostic Laboratory Immunology, 2001
- Pneumococcal Type 22F Polysaccharide Absorption Improves the Specificity of a Pneumococcal-Polysaccharide Enzyme-Linked Immunosorbent AssayClinical and Diagnostic Laboratory Immunology, 2001
- Are the Opsonophagocytic Activities of Antibodies in Infant Sera Measured by Different Pneumococcal Phagocytosis Assays Comparable?Clinical and Diagnostic Laboratory Immunology, 2001
- Efficacy of a Pneumococcal Conjugate Vaccine against Acute Otitis MediaNew England Journal of Medicine, 2001
- A MULTI-LABORATORY EVALUATION OF AN ENZYME-LINKED IMMUNOASSAY QUANTITATING HUMAN ANTIBODIES TOSTREPTOCOCCUS PNEUMONIAEPOLYSACCHARIDESImmunological Investigations, 2001
- Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in childrenThe Pediatric Infectious Disease Journal, 2000
- Which Pneumococcal Serogroups Cause the Most Invasive Disease: Implications for Conjugate Vaccine Formulation and Use, Part IClinical Infectious Diseases, 2000
- Characterization of pneumococcal specific antibodies in healthy unvaccinated adultsVaccine, 1998
- Opsonization And Antibodies To Capsular And Cell Wall Polysaccharides Of Streptococcus PneumoniaeThe Journal of Infectious Diseases, 1994